POS0689 WINDOW OF OPPORTUNITY IN THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE WITH ABATACEPT. NATIONAL MULTICENTER STUDY OF 526 PATIENTS
Authors: A. Serrano-Combarro, B. Atienza-Mateo, L. Ibarrola Paino, I. Casafont-Solé, J. Loarce-Martos, J. M. Blanco-Madrigal, S. Castañeda, R. Ortega-Castro, N. Mena-Vázquez, N. Vegas-Revenga, L. Domínguez Casas, C. Peralta-Ginés, M. Retuerto-Guerrero, L. Pérez Albaladejo, R. López-Sánchez, M. G. Mazano Canabal, A. Brandy-Garcia, P. López Viejo, G. Bonilla, O. Maiz, M. D. C. Carrasco Cubero, M. Garijo Bufort, A. Urruticoechea-Arana, S. Ordoñez, C. González-Montagut Gómez, A. García-Valle, J. R. De Dios Jiménez de Aberásturi, M. Martín López, T. Vazquez Rodriguez, D. Fernandez-Lozano, I. Braña Abascal, R. B. Melero-González, E. Giner, V. Ruiz, C. Ventín-Rodríguez, M. Rodriguez Lopez, P. Andújar-Brazal, J. Fernández-Melón, L. M. López, J. R. Lamúa Riazuelo, A. Pàmies, C. Fernández-Díaz, J. Loricera, D. Ferrer, R. Blanco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD <b>[1-2].</b> <h3>Objectives:</h3> To compare the efficacy of ABA in RA-ILD patients according to ILD duration. <h3>Methods:</h3> National multicenter study of 526 RA-ILD patients treated with ABA. Patients with ABA initiation early in the disease (during the first 6 months since ILD diagnosis) were compared to those in whom ABA was started after 2 years of ILD diagnosis ("early" vs. "late" group, respectively). We analyzed in the 2 groups the following outcomes: <b>a</b>) forced vital capacity (FVC), <b>b</b>) diffusing capacity of the lungs for carbon monoxide (DLCO), <b>c</b>) chest high resolution computed tomography (HRCT), <b>d</b>) dyspnea (modified Medical Research Council scale), and <b>e</b>) arthritis activity (DAS28-ESR or clinical records). <h3>Results:</h3> A total of 216 patients were included in the "early" group and 165 patients in the "late" group. Baseline demographic and clinical characteristics are shown in Table 1. Mean baseline values of FVC were significantly higher in the "early" group. The evolution of FVC and DLCO for 48 months is shown in Figure 1. Both parameters remained stable during 48 months of ABA therapy, with statistically significant differences found in case of FVC (although lower stable values of FVC in the "late" group). Available chest HRCT images improved/ stabilized in 76% and 54% of patients in the "early" and "late" group, respectively. Stabilization or improvement of dyspnea was found in most patients of both groups. <h3>Conclusion:</h3> Treatment with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. However, our results suggest that the same treatment (ABA) prescribed early in RA-ILD, may be preferable to preserve lung function ("window of opportunity"). <h3>REFERENCES:</h3> [1] Fernández-Díaz C, et al. Rheumatology (Oxford). 2020 Dec 1;59(12):3906-3916. [2] Fernández-Díaz C, et al. Rheumatology (Oxford). 2021 Dec 24;61(1):299-308. <b>Table 1.</b> Main general features at baseline of RA-ILD patients with "early" vs. "late" initiation of ABA in ILD course. IFX: Infliximab; ADA: Adalimumab; ETA: Etanercept. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Ana Serrano-Combarro: None declared, Belén Atienza-Mateo: None declared, Libe Ibarrola Paino: None declared, Ivette Casafont-Solé: None declared, Jesús Loarce-Martos: None declared, Juan María Blanco-Madrigal: None declared, Santos Castañeda: None declared, Rafaela Ortega-Castro: None declared, Natalia Mena-Vázquez: None declared, Nuria Vegas-Revenga: None declared, Lucía Domínguez Casas: None declared, Cilia Peralta-Ginés: None declared, M. Retuerto-Guerrero: None declared, Lorena Pérez Albaladejo: None declared, Ruben López-Sánchez: None declared, Mª Guadalupe Mazano Canabal: None declared, Anahy Brandy-Garcia: None declared, Patricia López Viejo: None declared, Gema Bonilla: None declared, Olga Maiz: None declared, Maria del Carmen Carrasco Cubero: None declared, Marta Garijo Bufort: None declared, Ana Urruticoechea-Arana: None declared, Sergi Ordoñez: None declared, C. González-Montagut Gómez: None declared, Andrea García-Valle: None declared, Juan Ramón De Dios Jiménez de Aberásturi: None declared, María Martín López: None declared, Tomas Vazquez Rodriguez: None declared, Delia Fernandez-Lozano: None declared, Ignacio Braña Abascal: None declared, Rafael B Melero-González: None declared, EMILIO GINER: None declared, Virginia Ruiz: None declared, Clara Ventín-Rodríguez: None declared, Marina Rodriguez Lopez: None declared, Pablo Andújar-Brazal: None declared, J. Fernández-Melón: None declared, Lilian Maria López: None declared, Jose Ramón Lamúa Riazuelo: None declared, Anna Pàmies: None declared, Carlos Fernández-Díaz: None declared, Javier Loricera: None declared, Diego Ferrer: None declared, Ricardo Blanco Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen, Galapagos and MSD, Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen and MSD, Abbvie, MSD, novartis and Roche.